The Hellenic Competition Authority fines a pharmaceutical company for reducing supplies of medicines to wholesalers (Glaxosmithline)

On 11 July 2018, the Hellenic Competition Commission (“HCC”) adopted a decision (the “Decision”) fining Glaxosmithkline (“GSK”) a total of €4.1 million for abusing its dominant position in relation to two pharmaceutical products: Imigran (an anti-migraine product) and Lamictal (an anticonvulsant). Following changes in GSK’s system of distribution which involved stopping meeting orders placed by wholesalers and then resuming orders but in limited quantities,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Tim Kasten, The Hellenic Competition Authority fines a pharmaceutical company for reducing supplies of medicines to wholesalers (Glaxosmithline), 11 July 2018, e-Competitions Bulletin July 2018, Art. N° 87554

Visites 510

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues